As you may know, the pharmaceutical industry is highly regulated. In order to have an open dialogue on Facebook and other social media sites, there are important rules that we must follow.
This site is not intended as a forum for discussing Cycle Pharmaceuticals or other companies' medicines, including the reporting of side effects associated with the use of prescription drugs, or for medical advice. If you have any questions about a Cycle Pharmaceutical therapy or medicine, visit our website at www.cyclepharma.com.
Information provided by this site is intended for adults, 18 years of age or older. As with any Facebook account, your interactions may be seen by other Facebook users. We reserve the right to remove comments or block users who violate the terms of use.
Commenting Policy:
While we encourage and welcome healthy debate and conversation on our Facebook page, we have a strict policy against personal attacks and derogatory language. If we feel you've crossed the line, we reserve the right to remove your post in order to maintain an environment of civil and respectful interaction.
For more information about Cycle Pharmaceuticals' policies please visit: www.cyclepharma.com/policies
Overview
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 8, 2020 | Cycle Pharmaceuticals secures $25 million debt financing | Cycle Pharmaceuticals secures $25 million debt financing 08-09-2020 Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, announced that i... |
| Sep 8, 2020 | Cycle Pharmaceuticals secures $25 million debt financing | Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, announced that it has executed a definitive agreement for a $25 million credit facil... |
| Sep 7, 2020 | Cycle Pharmaceuticals Secures $25M Debt Financing | Cycle Pharmaceuticals, a Cambridge, England-based patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, has executed a definitive agreement for a $25m credit facility with Deutsche Bank AG... |
Reviews 0
FAQ about Cycle Pharmaceuticals
When was Cycle Pharmaceuticals founded?
Cycle Pharmaceuticals was founded in 2012.
How much funding has Cycle Pharmaceuticals raised?
Cycle Pharmaceuticals has raised $25M in total across 1 funding round.
What has the press written about Cycle Pharmaceuticals?
Parsers VC has collected 4 articles mentioning Cycle Pharmaceuticals, among them “Cycle Pharmaceuticals secures $25 million debt financing” (Sep 8, 2020) and “Cycle Pharmaceuticals secures $25 million debt financing” (Sep 8, 2020).
Is Cycle Pharmaceuticals still active?
Yes, Cycle Pharmaceuticals is active; its latest activity on Parsers VC dates from Aug 12, 2026.